These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33622325)

  • 1. Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells.
    Yang N; Singhera GK; Yan YX; Pieper MP; Leung JM; Sin DD; Dorscheid DR
    Respir Res; 2021 Feb; 22(1):65. PubMed ID: 33622325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ▼Olodaterol--another LABA for COPD.
    Drug Ther Bull; 2015 Apr; 53(4):42-5. PubMed ID: 25858815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
    Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
    Roskell NS; Anzueto A; Hamilton A; Disse B; Becker K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():813-24. PubMed ID: 25114521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
    Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
    Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
    Melani AS
    Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
    Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
    Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
    Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olodaterol: first global approval.
    Gibb A; Yang LP
    Drugs; 2013 Nov; 73(16):1841-6. PubMed ID: 24158691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
    Ferguson GT; Feldman GJ; Hofbauer P; Hamilton A; Allen L; Korducki L; Sachs P
    Int J Chron Obstruct Pulmon Dis; 2014; 9():629-45. PubMed ID: 24966672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol.
    Criner G; Duffy S
    Curr Med Res Opin; 2021 Feb; 37(2):275-284. PubMed ID: 33095662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.
    Lee HW; Kim HJ; Lee CH
    Br J Clin Pharmacol; 2017 Jun; 83(6):1166-1175. PubMed ID: 27957746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
    Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
    Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.